$heff's $tation of $tocks & $olid DD

[Aggie9518]

More ACHN news... UP Premarket...$5 Target

Wedbush upgrades Achillion Pharmaceuticals (Nasdaq: ACHN) from Neutral to Outperform. Price target $5.

Wedbush analyst says, "Our increased confidence of an ACH-1625 partnership, which if materialized, could move the stock to our PT of $5. (1) Data from the first two cohorts from the Phase Ib study suggest that ACH-1625’s single agent potency (3.94-4.25 log drop) measures at the high end of the range among the HCV PIs in the clinic (the highest short term single agent viral load drop reported is 4.6 log), and the prolonged viral suppression after 5 days of dosing may indicate a robust resistance profile in addition to high potency, which can be a differentiating point for ACH-1625 among the PIs; (2) Our increasing conviction that serious HCV players in the industry need to position themselves for the STAT-C combination game during 2010, and it appears to us that there are more players than attractive HCV assets that are available. As few companies have more than two classes of molecules in their pipeline, we expect elevated level of deal-making activities in 2010."

http://www.streetinsider.com/Upgrades/Wedbush+Upgrades+Achillion+Pharmaceuticals+%28ACHN%29+to+Outperform/5297674.html